Cyhoeddiadau
2021
- Russell, N. H.et al. 2021. Outcomes of older patients aged 60 to 70 years undergoing reduced intensity transplant for acute myeloblastic leukaemia: results of the NCRI acute myeloid leukemia 16 trial. Haematologica (10.3324/haematol.2021.279010)
- Stimpson, M. L.et al. 2021. CD4+ T cells from patients with glucocorticoid-refractory immune thrombocytopenia have altered cytokine expression. British Journal of Haematology (10.1111/bjh.17884)
- Bradbury, C. A.et al. 2021. Mycophenolate mofetil for first-line treatment of immune thrombocytopenia. New England Journal of Medicine 385(10), pp. 885-895. (10.1056/NEJMoa2100596)
- Dennis, M.et al. 2021. A randomised evaluation of low-dose cytosine arabinoside (ara-C) plus tosedostat versus low-dose ara-C in older patients with acute myeloid leukaemia: results of the LI-1 trial. British Journal of Haematology 194(2), pp. 298-308. (10.1111/bjh.17501)
- Burnett, A. K.et al. 2021. Defining the optimal total number of chemotherapy courses in younger patients with acute myeloid leukemia: a comparison of three versus four courses. Journal of Clinical Oncology 39(8), pp. 890-901. (10.1200/JCO.20.01170)
2020
- Greenwood, R.et al. 2020. Letter on Predicting the number of sites needed to deliver a multicentre clinical trial within a limited time frame in the UK. Trials 21(1), article number: 873. (10.1186/s13063-020-04798-x)
2018
- Burnett, A. K.et al. 2018. A comparison of FLAG-Ida and daunorubicin combined with clofarabine in high-risk acute myeloid leukaemia: data from the UK NCRI AML17 Trial. Leukemia 32, pp. 2693-2714. (10.1038/s41375-018-0148-3)
- Freeman, S. D.et al. 2018. Measurable residual disease at induction redefines partial response in acute myeloid leukemia and stratifies outcomes in patients at standard risk without NPM1 mutations. Journal of Clinical Oncology 36(14), pp. 1486-1497. (10.1200/JCO.2017.76.3425)
2017
- Knapper, S.et al. 2017. A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML. Blood 129(9), pp. 1143-1154. (10.1182/blood-2016-07-730648)
2016
- Burnett, A.et al. 2016. Defining the dose of gemtuzumab ozogamicin in combination with induction chemotherapy in acute myeloid leukemia: a comparison of 3 mg/m2 with 6 mg/m2 in the NCRI AML17 trial. Haematologica 101(6), pp. 724-731. (10.3324/haematol.2016.141937)
2015
- Burnett, A. K.et al. 2015. A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients. Blood 125(25), pp. 3878-3885. (10.1182/blood-2015-01-623447)
- Khan, N.et al. 2015. An immunophenotypic pre-treatment predictor for poor response to induction chemotherapy in older acute myeloid leukaemia patients: blood frequency of CD34+ CD38 lowblasts. British Journal of Haematology 170(1), pp. 80-84. (10.1111/bjh.13398)
- Dennis, M.et al. 2015. Vosaroxin and vosaroxin plus low-dose Ara-C (LDAC) vs low-dose Ara-C alone in older patients with acute myeloid leukemia. Blood 125(19), pp. 2923-2932. (10.1182/blood-2014-10-608117)